| Title |
Treatment Options for Carbapenem-Resistant and Extensively Drug-Resistant Acinetobacterbaumannii Infections
|
|---|---|
| Published in |
Drugs, August 2014
|
| DOI | 10.1007/s40265-014-0267-8 |
| Pubmed ID | |
| Authors |
J. Alexander Viehman, M. Hong Nguyen, Yohei Doi |
| Abstract |
Acinetobacter baumannii is a leading cause of healthcare-associated infections worldwide. Because of various intrinsic and acquired mechanisms of resistance, most β-lactam agents are not effective against many strains, and carbapenems have played an important role in therapy. Recent trends show many infections are caused by carbapenem-resistant or even extensively drug-resistant (XDR) strains, for which effective therapy is not well established. Evidence to date suggests that colistin constitutes the backbone of therapy, but the unique pharmacokinetic properties of colistin have led many to suggest the use of combination antimicrobial therapy. However, the combination of agents and dosing regimens that delivers the best clinical efficacy while minimizing toxicity is yet to be defined. Carbapenems, sulbactam, rifampin and tigecycline have been the most studied in the context of combination therapy. Most data regarding therapy for invasive, resistant A. baumannii infections come from uncontrolled case series and retrospective analyses, though some clinical trials have been completed and others are underway. Early institution of appropriate antimicrobial therapy is shown to consistently improve survival of patients with carbapenem-resistant and XDR A. baumannii infection, but the choice of empiric therapy in these infections remains an open question. This review summarizes the most current knowledge regarding the epidemiology, mechanisms of resistance, and treatment considerations of carbapenem-resistant and XDR A. baumannii. |
X Demographics
The data shown below were collected from the profiles of 12 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 2 | 17% |
| United Kingdom | 1 | 8% |
| Colombia | 1 | 8% |
| Unknown | 8 | 67% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 8 | 67% |
| Scientists | 2 | 17% |
| Practitioners (doctors, other healthcare professionals) | 2 | 17% |
Mendeley readers
The data shown below were compiled from readership statistics for 237 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | <1% |
| Argentina | 1 | <1% |
| Unknown | 234 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 35 | 15% |
| Student > Ph. D. Student | 33 | 14% |
| Student > Master | 29 | 12% |
| Student > Bachelor | 28 | 12% |
| Student > Postgraduate | 18 | 8% |
| Other | 39 | 16% |
| Unknown | 55 | 23% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 59 | 25% |
| Biochemistry, Genetics and Molecular Biology | 29 | 12% |
| Immunology and Microbiology | 26 | 11% |
| Agricultural and Biological Sciences | 22 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 18 | 8% |
| Other | 23 | 10% |
| Unknown | 60 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 December 2018.
All research outputs
#5,260,607
of 25,718,113 outputs
Outputs from Drugs
#801
of 3,479 outputs
Outputs of similar age
#48,036
of 242,274 outputs
Outputs of similar age from Drugs
#12
of 36 outputs
Altmetric has tracked 25,718,113 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,479 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.0. This one has done well, scoring higher than 76% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 242,274 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 80% of its contemporaries.
We're also able to compare this research output to 36 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 66% of its contemporaries.